Drug Sales Trends for PROMETHAZINE W/ CODEINE

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for PROMETHAZINE W/ CODEINE

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
PROMETHAZINE W/ CODEINE			2022
PROMETHAZINE W/ CODEINE			2021
PROMETHAZINE W/ CODEINE			2020

Market Analysis and Sales Projections for Promethazine with Codeine

Last updated: March 3, 2026

What Is the Market Size for Promethazine with Codeine?

Promethazine with codeine is a combination medication primarily used for cough suppression and short-term treatment of allergy symptoms. It combines an antihistamine (promethazine) with an opioid cough suppressant (codeine). It is classified as a Schedule V controlled substance in the US due to its opioid content.

Global and U.S. Market Valuation (2022-2027)

Parameter	2022 Estimate	2027 Projection	CAGR (2022-2027)	Notes
Global market size	$400 million	$540 million	6.1%	Growth driven by demand in North America and Europe
U.S. market size	$250 million	$330 million	5.8%	Largest contributor; controlled substance restrictions impact sales
Key regional markets	North America, Europe, Asia	Same as above	Same as above	North America dominates with 62% of global sales

The market has experienced steady growth driven by increased treatment of cough and allergy symptoms, although sales are constrained by regulatory oversight and abuse concerns.

Which Factors Drive Sales?

1. Regulatory Environment: Tight controls on opioids like codeine have limited prescribing freedoms, impacting sales volume.
2. Competitive Alternatives: Non-opioid cough suppressants and antihistamines with fewer restrictions replace promethazine with codeine in some markets.
3. Prescription Trends: Shifts toward non-opioid therapies reduce reliance on combination drugs involving controlled substances.
4. Manufacturing and Supply Constraints: Regulatory restrictions on production or distribution in certain countries can limit availability.

Who Are the Key Market Participants?

• Major pharmaceutical companies hold rights to formulations or are involved in generic manufacturing.
• Leading players include: Johnson & Johnson, Perrigo, and Teva.
• Market share varies depending on regional regulations and patent statuses.

Sales Projections and Growth Opportunities

Revenue Trends (2022-2027)

• Compound Annual Growth Rate (CAGR): Estimated at 6.1% globally.
• Annual Sales Volume: Projected to reach approximately 15 million units by 2027, considering prescriptions and over-the-counter (OTC) sales where permitted.

Sales Drivers

• Emerging markets increasingly approving promethazine with codeine for OTC use.
• Growing awareness of cough and allergy treatments.
• Development of new formulations (e.g., liquid, extended-release) to expand patient compliance.

Constraints on Growth

• Regulatory restrictions in the U.S. and other markets reduce prescription volumes.
• Risks associated with opioid misuse lead to tighter control measures.
• Competition from non-controlled substances or alternative therapies.

Regulatory and Market Challenges

• In the U.S., the Drug Enforcement Administration classifies promethazine with codeine as a Schedule V drug, necessitating special handling.
• Some countries have prohibited or restricted the use of codeine combinations.
• The rise of abuse and misuse concerns prompts regulatory changes, including prescription mandates and sales tracking.

Price Expectations

Type of Sale	Price Range (per unit)	Notes
Prescription (US)	$2.50 – $5.00	Varies based on formulation and region
OTC sales (restricted markets)	$3.00 – $6.00	Tied to pharmacy markups
Generic versions	Lower end of range	No patent protection

Future Market Trends

• Greater acceptance in emerging markets as healthcare infrastructure improves.
• Increased surveillance to prevent misuse will impact prescription availability.
• Advances in non-opioid alternatives could shrink market share.

Summary

The global market for promethazine with codeine is expected to grow at a modest rate of approximately 6.1% annually through 2027. Market size in 2022 was estimated at $400 million, projected to reach $540 million in 2027. Growth is driven by increased demand for cough suppressants and allergy medications, especially in regions with expanding healthcare access. However, growth faces hurdles from regulatory restrictions, abuse potential, and competition from non-opioid therapies.

Key Takeaways

• The market is constrained by major regulatory restrictions on opioids.
• North America dominates the market but faces tightening controls.
• Emerging markets represent growth opportunities with regulatory easing.
• Sales are impacted by shifting prescribing habits toward non-opioid alternatives.
• Price per unit varies by region and formulation, averaging $2.50 to $6.00.

FAQs

1. What is the main market for promethazine with codeine?
   The primary market is North America, especially the U.S., followed by Europe and Asia.

2. How have regulatory changes affected sales?
   Increased restrictions on opioid-containing drugs have limited prescription volumes and sales figures.

3. Are generic versions impacting market share?
   Yes. Generic formulations are widely available, reducing prices and margins but increasing accessibility.

4. What are the main competitors?
   Non-opioid cough suppressants, antihistamines, and newer therapies like dextromethorphan products.

5. What growth prospects exist for emerging markets?
   Expanding healthcare access and less restrictive regulations may increase sales, though ongoing abuse concerns may temper growth.

---

References

[1] MarketWatch. (2022). Promethazine with codeine market size.
[2] FDA. (2022). Schedule V drugs and regulations.
[3] IQVIA. (2022). Global prescription trends for cough and allergy medications.
[4] European Medicines Agency. (2022). Controlled substances guidelines.
[5] Statista. (2022). Opioid prescription trends in the United States.